JP7121724B2 - ヒト抗体、医薬組成物及び方法 - Google Patents

ヒト抗体、医薬組成物及び方法 Download PDF

Info

Publication number
JP7121724B2
JP7121724B2 JP2019504699A JP2019504699A JP7121724B2 JP 7121724 B2 JP7121724 B2 JP 7121724B2 JP 2019504699 A JP2019504699 A JP 2019504699A JP 2019504699 A JP2019504699 A JP 2019504699A JP 7121724 B2 JP7121724 B2 JP 7121724B2
Authority
JP
Japan
Prior art keywords
cancer
seq
antibody
nos
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019504699A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532023A5 (enExample
JP2019532023A (ja
Inventor
ユイ，チュヨン－ダー・トニー
チャン，ウォーン・ウオン
リー，シュウ－ユイ
ライ，ジエン－シーン
チェン，イー－ジュイ
Original Assignee
オービーアイ ファーマ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オービーアイ ファーマ，インコーポレイテッド filed Critical オービーアイ ファーマ，インコーポレイテッド
Publication of JP2019532023A publication Critical patent/JP2019532023A/ja
Publication of JP2019532023A5 publication Critical patent/JP2019532023A5/ja
Priority to JP2022074216A priority Critical patent/JP2022110007A/ja
Application granted granted Critical
Publication of JP7121724B2 publication Critical patent/JP7121724B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019504699A 2016-07-29 2017-07-31 ヒト抗体、医薬組成物及び方法 Active JP7121724B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022074216A JP2022110007A (ja) 2016-07-29 2022-04-28 ヒト抗体、医薬組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662368407P 2016-07-29 2016-07-29
US62/368,407 2016-07-29
PCT/US2017/044713 WO2018023121A1 (en) 2016-07-29 2017-07-31 Human antibodies, pharmaceutical compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022074216A Division JP2022110007A (ja) 2016-07-29 2022-04-28 ヒト抗体、医薬組成物及び方法

Publications (3)

Publication Number Publication Date
JP2019532023A JP2019532023A (ja) 2019-11-07
JP2019532023A5 JP2019532023A5 (enExample) 2020-09-03
JP7121724B2 true JP7121724B2 (ja) 2022-08-18

Family

ID=61017454

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019504699A Active JP7121724B2 (ja) 2016-07-29 2017-07-31 ヒト抗体、医薬組成物及び方法
JP2022074216A Withdrawn JP2022110007A (ja) 2016-07-29 2022-04-28 ヒト抗体、医薬組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022074216A Withdrawn JP2022110007A (ja) 2016-07-29 2022-04-28 ヒト抗体、医薬組成物及び方法

Country Status (7)

Country Link
US (1) US11643456B2 (enExample)
EP (1) EP3491026A4 (enExample)
JP (2) JP7121724B2 (enExample)
KR (1) KR102528998B1 (enExample)
CN (1) CN110062767B (enExample)
TW (1) TWI786054B (enExample)
WO (1) WO2018023121A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3500716B2 (ja) 1994-08-26 2004-02-23 株式会社村田製作所 電子部品収納カセット

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015032713B1 (pt) 2013-09-17 2023-03-21 Obi Pharma, Inc Composto, composição farmacêutica, uso de uma quantidade terapeuticamente efetiva da composição farmacêutica, e uso do composto
US10935544B2 (en) 2015-09-04 2021-03-02 Obi Pharma, Inc. Glycan arrays and method of use
BR112018070097A2 (pt) 2016-03-29 2019-02-12 Obi Pharma, Inc. anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
KR20230110820A (ko) 2016-04-22 2023-07-25 오비아이 파머 인코퍼레이티드 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에의한 암 면역요법
CN110072545A (zh) 2016-07-27 2019-07-30 台湾浩鼎生技股份有限公司 免疫原性/治疗性聚糖组合物及其用途
US11643456B2 (en) 2016-07-29 2023-05-09 Obi Pharma, Inc. Human antibodies, pharmaceutical compositions and methods
TWI822055B (zh) 2016-11-21 2023-11-11 台灣浩鼎生技股份有限公司 共軛生物分子、醫藥組成物及方法
CN110573528B (zh) * 2017-03-29 2023-06-09 豪夫迈·罗氏有限公司 针对共刺激性tnf受体的双特异性抗原结合分子
JP2020531430A (ja) * 2017-08-16 2020-11-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗体を標的とする抗ｃｔｌａ４プロボディ療法
US10751399B2 (en) * 2018-03-20 2020-08-25 Cho Pharma Usa, Inc. Chimeric antigen receptors that bind to SSEA4 and uses thereof
TW202504930A (zh) 2018-06-27 2025-02-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
US11103567B2 (en) * 2018-12-06 2021-08-31 Academia Sinica Glycoconjugate vaccines, preparation method and uses thereof
KR20220016044A (ko) * 2019-03-28 2022-02-08 밍-테인 라이 글로보-h 관련 암 치료법을 위한 동반 진단 검정
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160102151A1 (en) 2014-01-16 2016-04-14 Academia Sinica Compositions and methods for treatment and detection of cancers

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
AU519567B2 (en) 1977-07-13 1981-12-10 Akzo Nv Psychopharmacological penta and hexa-peptides
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4849222A (en) 1987-03-24 1989-07-18 The Procter & Gamble Company Mixtures for treating hypercholesterolemia
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
EP0491007B1 (en) 1989-09-08 1996-03-13 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1992000373A1 (en) 1990-06-29 1992-01-09 Biosource Genetics Corporation Melanin production by transformed microorganisms
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DE69222303T2 (de) 1991-04-30 1998-01-22 Eukarion Inc Kationisierte antikörper gegen intrazelluläre eiweisse
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
US5288502A (en) 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU687010B2 (en) 1992-07-17 1998-02-19 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
ATE191853T1 (de) 1992-07-27 2000-05-15 Us Health Zielgerichte liposome zur blut-hirne schranke
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
DE69431404T2 (de) 1993-10-22 2003-04-30 Genentech Inc., San Francisco Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe
US6544952B1 (en) 1994-03-15 2003-04-08 Sloan-Kettering Institute For Cancer Research Synthesis of glycoconjugates of the globo-H epitope and uses thereof
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
AU2660397A (en) 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
EA001595B1 (ru) 1996-04-12 2001-06-25 Варнер-Ламберт Компани Необратимые ингибиторы тирозинкиназ
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
AU776632B2 (en) 1999-02-17 2004-09-16 Glycominds Ltd. Combinatorial complex carbohydrate libraries and methods for the manufacture and uses thereof
ES2572834T3 (es) 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
US7824687B2 (en) 1999-08-20 2010-11-02 Sloan-Kettering Institute For Cancer Research Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof
US7854934B2 (en) 1999-08-20 2010-12-21 Sloan-Kettering Institute For Cancer Research Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
US20020065259A1 (en) 2000-08-30 2002-05-30 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US20030104402A1 (en) 2001-01-23 2003-06-05 University Of Rochester Methods of producing or identifying intrabodies in eukaryotic cells
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
AU2002322720B2 (en) 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
CA2454853A1 (en) 2001-08-14 2003-02-27 Biomira, Inc. Imunogenic conjugate of carbohydrate haptens and aggregated protein carrier
CA2467242A1 (en) 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
WO2003077945A1 (en) 2002-03-14 2003-09-25 Medical Research Council Intracellular antibodies
US20050180972A1 (en) 2002-07-31 2005-08-18 Wahl Alan F. Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
WO2004042017A2 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
JP4995423B2 (ja) 2002-12-03 2012-08-08 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア
EP1585768A2 (en) 2003-01-23 2005-10-19 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
US20060035267A1 (en) 2003-04-09 2006-02-16 Livingston Philip O Optimal polyvalent vaccine for cancer
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
RU2385163C2 (ru) 2003-08-25 2010-03-27 ОнкоМун Профилактическая противораковая вакцина
JP2007505142A (ja) 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
JP2007527539A (ja) 2004-03-05 2007-09-27 ザ スクリプス リサーチ インスティテュート ハイスループットグリカンマイクロアレイ
EP1776105A2 (en) 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
US20060287263A1 (en) 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing antigen-specific immune responses
CN103356706B (zh) 2005-03-31 2016-01-20 斯丹姆涅恩有限公司 促进无疤愈合或改善皮肤外观的美容制剂
SI1934174T1 (sl) 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
EP1951281B1 (en) 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
JP5391073B2 (ja) 2006-11-27 2014-01-15 ディアデクサス インコーポレーテッド Ｏｖｒ１１０抗体組成物および使用方法
WO2009035494A2 (en) 2007-07-30 2009-03-19 The Scripps Research Institute Methods for producing anti-glycan antibodies, vaccines and methods for treating cancer or infectious disease
CA2701612A1 (en) 2007-10-05 2009-04-09 Takeda Pharmaceutical Company Limited Neuromedin u derivative
EP2268315B1 (en) 2008-03-31 2019-07-31 Freie Universität Berlin Drug conjugates with polyglycerols
KR102256410B1 (ko) 2008-04-08 2021-05-26 슬로안-케테링인스티튜트퍼캔서리서치 트리테르펜 사포닌, 그의 합성 방법, 및 그의 용도
TWI461531B (zh) * 2008-05-07 2014-11-21 Shi Lung Lin 使用可誘導之重組核醣核酸生成不具癌細胞特性之類胚胎幹細胞
AU2009268937A1 (en) 2008-06-16 2010-01-14 Aj Park Compositions for inducing immune responses specific to Globo H and SSEA3 and uses thereof in cancer treatment
MX2010013931A (es) * 2008-06-16 2011-06-01 Academia Sinica Diagnosis de cancer basada en niveles de anticuerpos contra globo h y sus fragmentos.
KR101677279B1 (ko) 2009-06-16 2016-11-29 아카데미아 시니카 신규한 당지질 애주번트를 갖는 ｇｌｏｂｏ ｈ 및 관련 항암 백신
EP2347769A1 (en) 2010-01-20 2011-07-27 Glycotope GmbH Cancer stem cell markers and uses thereof
CA2801922A1 (en) 2010-06-11 2011-12-15 Sloan-Kettering Institute For Cancer Research Multivalent glycopeptide constructs and uses thereof
US9175326B2 (en) 2011-03-03 2015-11-03 University Of Maryland, Baltimore Transglycosylation activity of glycosynthase mutants of an endo-beta-N-acetylglucosaminidase (endo-D) from streptococcus pneumoniae
EP2500035A1 (en) 2011-03-15 2012-09-19 Icon Genetics GmbH Pharmaceutical formulation containing immunglobulin
WO2012171020A1 (en) 2011-06-10 2012-12-13 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
IN2014DN06806A (enExample) 2012-02-10 2015-05-22 Univ Maryland
BR112014020826A8 (pt) 2012-02-24 2017-09-19 Stem Centrx Inc Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco – anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado
AU2013231638B2 (en) 2012-03-16 2017-10-12 Merck Patent Gmbh Targeting aminoacid lipids
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
CN111499679B (zh) 2013-01-04 2021-07-06 台湾浩鼎生技股份有限公司 具有较高碳水化合物抗原密度的疫苗及新颖皂素佐剂
US10307471B2 (en) 2013-05-02 2019-06-04 National Institute Of Advanced Industrial Science And Technology Immunity inducer for saccharide antigens
BR112015032713B1 (pt) 2013-09-17 2023-03-21 Obi Pharma, Inc Composto, composição farmacêutica, uso de uma quantidade terapeuticamente efetiva da composição farmacêutica, e uso do composto
AU2015206370A1 (en) 2014-01-16 2016-07-07 Academia Sinica Compositions and methods for treatment and detection of cancers
US20170335281A1 (en) 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
JP2017518958A (ja) * 2014-03-19 2017-07-13 マッカイ メディカル ファウンデイション ザ プレスビテリアン チャーチ イン タイワン マッカイ メモリアル ホスピタルＭａｃｋａｙ Ｍｅｄｉｃａｌ Ｆｏｕｎｄａｔｉｏｎ Ｔｈｅ Ｐｒｅｓｂｙｔｅｒｉａｎ Ｃｈｕｒｃｈ Ｉｎ Ｔａｉｗａｎ Ｍａｃｋａｙ Ｍｅｍｏｒｉａｌ Ｈｏｓｐｉｔａｌ 免疫原性グリコペプチドに対する抗体、それを含む組成物、及びそれらの使用
ES2693035T3 (es) 2014-04-01 2018-12-07 Miltenyi Biotec Gmbh SSEA4 y ST3GAL2 como biomarcadores de respuesta a fármacos quimioterapéuticos
CA2941029C (en) 2014-04-10 2021-02-16 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
KR102387122B1 (ko) 2014-08-19 2022-04-14 밀테니 비오텍 비.브이. & 씨오. 케이지 Ssea4 항원에 특이적인 키메라 항원 수용체
KR102702705B1 (ko) 2014-09-15 2024-09-04 오비아이 파머 인코퍼레이티드 면역원성/치료적 당접합체 조성물 및 그의 용도
AU2016209056B2 (en) 2015-01-24 2021-01-28 Academia Sinica Cancer markers and methods of use thereof
WO2016123593A1 (en) 2015-01-30 2016-08-04 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JP2018520679A (ja) 2015-06-29 2018-08-02 ザ・ジョンズ・ホプキンス・ユニバーシティー 免疫チェックポイントキメラ抗原受容体療法
CN108026518B (zh) 2015-07-16 2022-09-06 第一三共株式会社 新型endos突变型酶
US10935544B2 (en) 2015-09-04 2021-03-02 Obi Pharma, Inc. Glycan arrays and method of use
CA3000531A1 (en) 2015-10-07 2017-04-13 Obi Pharma, Inc. Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
BR112018070097A2 (pt) 2016-03-29 2019-02-12 Obi Pharma, Inc. anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
KR20230110820A (ko) 2016-04-22 2023-07-25 오비아이 파머 인코퍼레이티드 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에의한 암 면역요법
GB201611535D0 (en) 2016-07-01 2016-08-17 King S College London Methods and compositions for treating cancer with siglec-9 activity modulators
CN110072545A (zh) 2016-07-27 2019-07-30 台湾浩鼎生技股份有限公司 免疫原性/治疗性聚糖组合物及其用途
US11643456B2 (en) 2016-07-29 2023-05-09 Obi Pharma, Inc. Human antibodies, pharmaceutical compositions and methods
CA3034057A1 (en) 2016-08-22 2018-03-01 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
TWI822055B (zh) 2016-11-21 2023-11-11 台灣浩鼎生技股份有限公司 共軛生物分子、醫藥組成物及方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160102151A1 (en) 2014-01-16 2016-04-14 Academia Sinica Compositions and methods for treatment and detection of cancers

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3500716B2 (ja) 1994-08-26 2004-02-23 株式会社村田製作所 電子部品収納カセット

Also Published As

Publication number Publication date
TWI786054B (zh) 2022-12-11
KR20190026939A (ko) 2019-03-13
US20210284719A1 (en) 2021-09-16
JP2022110007A (ja) 2022-07-28
JP2019532023A (ja) 2019-11-07
US11643456B2 (en) 2023-05-09
TW201817743A (zh) 2018-05-16
KR102528998B1 (ko) 2023-05-03
EP3491026A4 (en) 2020-07-29
EP3491026A1 (en) 2019-06-05
CN110062767B (zh) 2023-07-11
CN110062767A (zh) 2019-07-26
WO2018023121A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
JP7121724B2 (ja) ヒト抗体、医薬組成物及び方法
US20230082122A1 (en) Diagnostic and therapeutic methods for cancer
ES2850428T3 (es) Procedimientos de monitorización y tratamiento del cáncer
TWI823859B (zh) 癌症之治療及診斷方法
ES2835866T3 (es) Procedimientos terapéuticos y de diagnóstico para el cáncer
CN109196121A (zh) 用于癌症的治疗和诊断方法
CN107532217A (zh) 用于癌症的治疗和诊断方法
JP7399895B2 (ja) Ｐｄ－１軸結合拮抗薬、白金剤、およびトポイソメラーゼｉｉ阻害剤で肺癌を治療する方法
CN109154027A (zh) 用于监测和治疗癌症的方法
KR20210034622A (ko) Pd-1 축 결합 길항제, 항 대사제, 및 백금 제제를 이용한 폐암 치료 방법
KR20210063330A (ko) 방광암에 대한 치료 및 진단 방법
JP2023520515A (ja) がんに対する治療方法及び診断方法
HK40005703B (en) Human antibodies, pharmaceutical compositions and methods
HK40005703A (en) Human antibodies, pharmaceutical compositions and methods
HK40050244A (en) Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
HK40018953A (en) Diagnostic and therapeutic methods for cancer
HK40002465A (en) Methods for monitoring and treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200727

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210720

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220531

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220601

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220620

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220621

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220712

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220805

R150 Certificate of patent or registration of utility model

Ref document number: 7121724

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150